Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 5
2005 6
2006 9
2007 4
2008 7
2009 10
2010 18
2011 10
2012 8
2013 13
2014 9
2015 10
2016 5
2017 7
2018 8
2019 21
2020 29
2021 20
2022 23
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients.
Coulon PG, Prakash S, Dhanushkodi NR, Srivastava R, Zayou L, Tifrea DF, Edwards RA, Figueroa CJ, Schubl SD, Hsieh L, Nesburn AB, Kuppermann BD, Bahraoui E, Vahed H, Gil D, Jones TM, Ulmer JB, BenMohamed L. Coulon PG, et al. Among authors: kuppermann bd. Front Immunol. 2024 Mar 28;15:1343716. doi: 10.3389/fimmu.2024.1343716. eCollection 2024. Front Immunol. 2024. PMID: 38605956 Free PMC article.
Global experience of faricimab in clinical settings - a review.
Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. Expert Opin Biol Ther. 2024 Apr;24(4):263-268. doi: 10.1080/14712598.2024.2336087. Epub 2024 Mar 29. Expert Opin Biol Ther. 2024. PMID: 38551188 Review.
A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
Prakash S, Dhanushkodi NR, Singer M, Quadiri A, Zayou L, Vahed H, Coulon PG, Ibraim IC, Tafoya C, Hitchcock L, Landucci G, Forthal DN, El Babsiri A, Tifrea DF, Figueroa CJ, Nesburn AB, Kuppermann BD, Gil D, Jones TM, Ulmer JB, BenMohamed L. Prakash S, et al. Among authors: kuppermann bd. bioRxiv [Preprint]. 2024 Feb 15:2024.02.14.580225. doi: 10.1101/2024.02.14.580225. bioRxiv. 2024. PMID: 38405942 Free PMC article. Preprint.
Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern.
Prakash S, Dhanushkodi NR, Zayou L, Ibraim IC, Quadiri A, Coulon PG, Tifrea DF, Suzer B, Shaik AM, Chilukuri A, Edwards RA, Singer M, Vahed H, Nesburn AB, Kuppermann BD, Ulmer JB, Gil D, Jones TM, BenMohamed L. Prakash S, et al. Among authors: kuppermann bd. Front Immunol. 2024 Jan 22;15:1328905. doi: 10.3389/fimmu.2024.1328905. eCollection 2024. Front Immunol. 2024. PMID: 38318166 Free PMC article.
In Memoriam: M. Cristina Kenney, MD, PhD (1949-2023).
Kuppermann BD, Palczewski K. Kuppermann BD, et al. Exp Eye Res. 2024 Jan 31:109805. doi: 10.1016/j.exer.2024.109805. Online ahead of print. Exp Eye Res. 2024. PMID: 38302293 No abstract available.
Biosimilar to Biosimilar Anti-VEGF Switching for Retinal Diseases.
Sharma A, Loewenstein A, Parachuri N, Kumar N, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. J Vitreoretin Dis. 2023 Sep 29;7(6):474-476. doi: 10.1177/24741264231202080. eCollection 2023 Nov-Dec. J Vitreoretin Dis. 2023. PMID: 37974924 No abstract available.
Aflibercept biosimilars - update on the development progress.
Sharma A, Loewenstein A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. Eye (Lond). 2024 Apr;38(5):824-825. doi: 10.1038/s41433-023-02813-4. Epub 2023 Nov 4. Eye (Lond). 2024. PMID: 37925561 No abstract available.
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?
Sharma A, Loewenstein A, Parachuri N, Kumar N, Rasal A, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: kuppermann bd. Eye (Lond). 2024 Feb;38(2):244-245. doi: 10.1038/s41433-023-02698-3. Epub 2023 Aug 30. Eye (Lond). 2024. PMID: 37648725 No abstract available.
215 results